Conatus Pharmaceuticals Company Profile (NASDAQ:CNAT)

About Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals logoConatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CNAT
  • CUSIP: N/A
  • Web: www.conatuspharma.com
Capitalization:
  • Market Cap: $170.12 million
  • Outstanding Shares: 30,004,000
Average Prices:
  • 50 Day Moving Avg: $5.42
  • 200 Day Moving Avg: $5.75
  • 52 Week Range: $1.45 - $9.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 27.00
  • P/E Growth: -0.33
Sales & Book Value:
  • Annual Revenue: $17.81 million
  • Price / Sales: 9.55
  • Book Value: $1.14 per share
  • Price / Book: 4.97
Profitability:
  • EBIDTA: ($25,060,000.00)
  • Return on Equity: -96.53%
  • Return on Assets: -33.58%
Debt:
  • Debt-to-Equity Ratio: 0.37%
  • Current Ratio: 2.77%
  • Quick Ratio: 2.77%
Misc:
  • Average Volume: 562,647 shs.
  • Beta: 1.27
  • Short Ratio: 3.7
 

Frequently Asked Questions for Conatus Pharmaceuticals (NASDAQ:CNAT)

What is Conatus Pharmaceuticals' stock symbol?

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) posted its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.02. The business earned $10 million during the quarter, compared to the consensus estimate of $9.33 million. During the same period last year, the business earned ($0.30) EPS. View Conatus Pharmaceuticals' Earnings History.

When will Conatus Pharmaceuticals make its next earnings announcement?

Conatus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for Conatus Pharmaceuticals.

Where is Conatus Pharmaceuticals' stock going? Where will Conatus Pharmaceuticals' stock price be in 2017?

7 equities research analysts have issued 1-year price objectives for Conatus Pharmaceuticals' stock. Their forecasts range from $7.00 to $26.00. On average, they expect Conatus Pharmaceuticals' stock price to reach $14.67 in the next year. View Analyst Ratings for Conatus Pharmaceuticals.

What are analysts saying about Conatus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Conatus Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Conatus presently has no approved product in its portfolio. However, its progress with the lead candidate, emricasan has been encouraging. Emricasan is in phase II development for the treatment of chronic liver disease, including NASH fibrosis. Conatus also plans to initiate studies on emricasan targeting different types of NASH patient populations. Moreover, the stock has outperformed the industry in the last one year. On the flip side, though emricasan is progressing well, it is still several years away from entering the market, if at all. Any development/regulatory setback could hamper Conatus’ prospects. Notably, several companies are working on developing treatments for NASH which might make the market competitive for emricasan. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters." (7/24/2017)
  • 2. Aegis analysts commented, "We believe that Novartis will likely exercise its option for worldwide exclusive rights to Emricasan. Potential Combination Products. Under the agreement, Novartis’ option includes the ability to develop products using either Emricasan as the sole active ingredient or in combination with other compounds in its pipeline (e.g., farnesoid X). The tiered royalties payable to Conatus for these potential combination products range from high-single digits to mid-teens and are subject to certain reductions." (3/16/2017)
  • 3. FBR & Co analysts commented, "We think the strong pairing formed when Conatus Pharmaceuticals signed an option, collaboration, and licensing agreement with Novartis (NVS) firmly de-risked the path for completing clinical development of CNAT's Phase III ready liver disease drug emricasan, which is the most clinically advanced drug candidate in liver cirrhosis. In particular, we look for CNAT to benefit from collaborative synergies with NVS's expertise in liver disease research, and its track record of success in drug development and commercialization. As it is now a key new program in NVS's pipeline of $1B-plus potential product candidates, we also think this deal validates the value of emricasan, with the $650M deal recognition of emricasan's potential application in liver diseases with different etiologies. Therefore, we reiterate our Outperform rating." (3/15/2017)

Who are some of Conatus Pharmaceuticals' key competitors?

Who are Conatus Pharmaceuticals' key executives?

Conatus Pharmaceuticals' management team includes the folowing people:

  • David F. Hale, Independent Chairman of the Board
  • Steven J. Mento Ph.D., President, Chief Executive Officer, Director
  • Keith W. Marshall, Chief Financial Officer, Principal Financial Officer, Chief Operating Officer, Executive Vice President
  • Alfred P. Spada Ph.D., Executive Vice President - Research & Development, Chief Scientific Officer
  • David T. Hagerty M.D., Executive Vice President, Clinical Development
  • Daniel L. Ripley, Senior Vice President - Business Development, Program and Alliance Management
  • Edward F. Smith III., Ph.D., Senior Vice President - Regulatory Affairs and Quality Assurance
  • Michelle L Vandertie, Acting Principal Accounting Officer
  • Daniel L. Kisner M.D., Additional Independent Director
  • Preston S. Klassen M.D., Additional Independent Director

Who owns Conatus Pharmaceuticals stock?

Conatus Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include MPM Asset Management LLC (4.24%), Acadian Asset Management LLC (4.20%), Vanguard Group Inc. (3.58%), AXA (1.60%), State Street Corp (1.21%) and Northern Trust Corp (1.06%). View Institutional Ownership Trends for Conatus Pharmaceuticals.

Who sold Conatus Pharmaceuticals stock? Who is selling Conatus Pharmaceuticals stock?

Conatus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including AXA. View Insider Buying and Selling for Conatus Pharmaceuticals.

Who bought Conatus Pharmaceuticals stock? Who is buying Conatus Pharmaceuticals stock?

Conatus Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, State Street Corp, Numeric Investors LLC, Northern Trust Corp, Vanguard Group Inc., Schwab Charles Investment Management Inc., Russell Investments Group Ltd. and Arrowstreet Capital Limited Partnership. View Insider Buying and Selling for Conatus Pharmaceuticals.

How do I buy Conatus Pharmaceuticals stock?

Shares of Conatus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Conatus Pharmaceuticals' stock price today?

One share of Conatus Pharmaceuticals stock can currently be purchased for approximately $5.67.


MarketBeat Community Rating for Conatus Pharmaceuticals (NASDAQ CNAT)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  207 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  297
MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Conatus Pharmaceuticals (NASDAQ:CNAT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.67 (158.67% upside)

Analysts' Ratings History for Conatus Pharmaceuticals (NASDAQ:CNAT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/3/2017Stifel NicolausReiterated RatingBuy$10.00HighView Rating Details
6/29/2017HC WainwrightReiterated RatingBuy$18.00HighView Rating Details
5/15/2017AegisReiterated RatingBuy$11.00N/AView Rating Details
3/15/2017FBR & CoReiterated RatingOutperform$16.00HighView Rating Details
12/23/2016SunTrust Banks, Inc.Reiterated RatingBuy$17.00 -> $26.00N/AView Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/4/2016Brean CapitalReiterated RatingBuy$7.00N/AView Rating Details
7/1/2016Roth CapitalInitiated CoverageBuy -> BuyN/AView Rating Details
9/24/2015Piper Jaffray CompaniesReiterated RatingHold$5.00N/AView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Conatus Pharmaceuticals (NASDAQ:CNAT)
Earnings by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)
Earnings History by Quarter for Conatus Pharmaceuticals (NASDAQ CNAT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.15)N/AView Earnings Details
8/2/2017Q2 2017($0.17)($0.19)$9.33 million$10.00 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.34)($0.14)$5.88 million$7.00 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.32)($0.35)$0.80 millionViewN/AView Earnings Details
11/8/2016Q3($0.34)($0.31)ViewListenView Earnings Details
8/3/2016Q216($0.38)($0.30)ViewN/AView Earnings Details
5/5/2016Q116($0.35)($0.35)ViewN/AView Earnings Details
3/9/2016Q4($0.37)($0.30)ViewListenView Earnings Details
11/4/2015Q315($0.38)($0.31)ViewN/AView Earnings Details
8/5/2015Q215($0.34)($0.31)ViewN/AView Earnings Details
5/7/2015Q115($0.35)($0.38)ViewListenView Earnings Details
3/11/2015Q414($0.49)($0.34)ViewListenView Earnings Details
11/12/2014Q3($0.43)($0.42)ViewN/AView Earnings Details
8/13/2014Q214($0.39)($0.34)ViewListenView Earnings Details
5/13/2014Q1($0.34)($0.34)ViewN/AView Earnings Details
3/27/2014($0.27)($0.33)ViewN/AView Earnings Details
11/14/2013Q3($0.20)($0.28)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)
2017 EPS Consensus Estimate: ($0.59)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.26)($0.01)($0.17)
Q2 20173($0.26)$0.00($0.17)
Q3 20173($0.26)($0.01)($0.11)
Q4 20173($0.26)($0.02)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Conatus Pharmaceuticals (NASDAQ:CNAT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Conatus Pharmaceuticals (NASDAQ:CNAT)
Insider Ownership Percentage: 13.90%
Institutional Ownership Percentage: 33.13%
Insider Trades by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)
Institutional Ownership by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)
Insider Trades by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/8/2015Daniel L KisnerDirectorBuy4,000$5.75$23,000.00View SEC Filing  
7/30/2013David F HaleDirectorBuy2,588$11.00$28,468.00View SEC Filing  
7/30/2013Luke EvninMajor ShareholderBuy165,265$11.00$1,817,915.00View SEC Filing  
7/30/2013Steven J MentoCEOBuy13,800$11.00$151,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Conatus Pharmaceuticals (NASDAQ:CNAT)
Latest Headlines for Conatus Pharmaceuticals (NASDAQ:CNAT)
Source:
DateHeadline
finance.yahoo.com logoHedge fund manager shuts firm to explore run for Connecticut governor
finance.yahoo.com - September 19 at 5:24 PM
nasdaq.com logoConatus (CNAT) Up 7% Since Earnings Report: Can It Continue? - Nasdaq
www.nasdaq.com - September 8 at 10:48 PM
finance.yahoo.com logoConatus (CNAT) Up 7% Since Earnings Report: Can It Continue?
finance.yahoo.com - September 8 at 5:44 PM
americanbankingnews.com logoConatus Pharmaceuticals Inc. (CNAT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 6 at 8:38 AM
americanbankingnews.com logoHead-To-Head Comparison: Minerva Neurosciences (NERV) versus Conatus Pharmaceuticals (CNAT)
www.americanbankingnews.com - September 2 at 2:18 PM
streetinsider.com logoConatus Pharmaceuticals (CNAT) Appoints Keith Marshall as COO and CFO
www.streetinsider.com - September 1 at 5:35 PM
streetinsider.com logoConatus Pharmaceuticals (CNAT) Appoints Keith Marshall as COO ... - StreetInsider.com
www.streetinsider.com - September 1 at 3:19 AM
finance.yahoo.com logoConatus Pharmaceuticals Appoints Keith W. Marshall as Executive Vice President, Chief Operating Officer and Chief Financial Officer
finance.yahoo.com - August 31 at 5:14 PM
globenewswire.com logoConatus to Present at Rodman & Renshaw Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - August 29 at 10:54 PM
finance.yahoo.com logoConatus to Present at Rodman & Renshaw Global Investment Conference
finance.yahoo.com - August 29 at 5:41 PM
zacks.com logoWill Conatus Key Candidate Emricasan Drive Long-Term Growth?
www.zacks.com - August 21 at 5:09 PM
seekingalpha.com logoConatus: Major Contender For The NASH Market - Seeking Alpha
seekingalpha.com - August 17 at 11:38 PM
americanbankingnews.com logoConatus Pharmaceuticals Inc. (CNAT) Expected to Announce Quarterly Sales of $13.46 Million
www.americanbankingnews.com - August 17 at 9:48 AM
americanbankingnews.com logoConatus Pharmaceuticals Inc. (NASDAQ:CNAT) Expected to Post Earnings of -$0.08 Per Share
www.americanbankingnews.com - August 15 at 2:18 AM
globenewswire.com logoConatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with ... - GlobeNewswire (press release)
globenewswire.com - August 14 at 5:44 PM
finance.yahoo.com logoConatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis
finance.yahoo.com - August 14 at 5:43 PM
americanbankingnews.com logoConatus Pharmaceuticals Inc. (CNAT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - August 12 at 11:58 AM
americanbankingnews.com logoConatus Pharmaceuticals Inc. Expected to Earn Q3 2017 Earnings of ($0.06) Per Share (CNAT)
www.americanbankingnews.com - August 7 at 7:08 AM
americanbankingnews.com logoConatus Pharmaceuticals Inc. Expected to Post FY2018 Earnings of $1.97 Per Share (NASDAQ:CNAT)
www.americanbankingnews.com - August 4 at 6:02 PM
nasdaq.com logoConatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates - Nasdaq
www.nasdaq.com - August 4 at 6:06 AM
zacks.com logoConatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates
www.zacks.com - August 3 at 5:12 PM
seekingalpha.com logoConatus' (CNAT) CEO Steve Mento on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 2 at 11:10 PM
finance.yahoo.com logoConatus reports 2Q loss
finance.yahoo.com - August 2 at 11:10 PM
americanbankingnews.com logoConatus Pharmaceuticals Inc. (CNAT) Announces Earnings Results
www.americanbankingnews.com - August 2 at 9:28 PM
finance.yahoo.com logoInvestor Network: Conatus Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - August 2 at 6:09 PM
finance.yahoo.com logoConatus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Program Updates
finance.yahoo.com - August 2 at 6:09 PM
americanbankingnews.com logo Brokerages Expect Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Will Announce Quarterly Sales of $7.93 Million
www.americanbankingnews.com - July 29 at 7:21 AM
americanbankingnews.com logoConatus Pharmaceuticals Inc. (CNAT) Expected to Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - July 27 at 8:09 PM
americanbankingnews.com logoConatus Pharmaceuticals (NASDAQ:CNAT) vs. Vertex Pharmaceuticals (VRTX) Head to Head Review
www.americanbankingnews.com - July 27 at 10:59 AM
zacks.com logoWhat's in Store for Conatus (CNAT) this Earnings Season?
www.zacks.com - July 27 at 3:31 AM
nasdaq.com logoWhat's in Store for Conatus (CNAT) this Earnings Season? - Nasdaq
www.nasdaq.com - July 26 at 5:55 PM
finance.yahoo.com logoWhat's in Store for Conatus (CNAT) this Earnings Season?
finance.yahoo.com - July 26 at 5:55 PM
finance.yahoo.com logoConatus Pharmaceuticals to Report Second Quarter 2017 Financial Results
finance.yahoo.com - July 26 at 5:55 PM
americanbankingnews.com logoConatus Pharmaceuticals Inc. (CNAT) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - July 25 at 7:22 AM
americanbankingnews.com logoConatus Pharmaceuticals Inc. (CNAT) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - July 24 at 1:36 PM
americanbankingnews.com logoConatus Pharmaceuticals Inc (CNAT) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 18 at 12:13 PM
americanbankingnews.com logoConatus Pharmaceuticals Inc. (CNAT) Short Interest Up 340.0% in June
www.americanbankingnews.com - July 14 at 7:34 AM
americanbankingnews.com logoConatus Pharmaceuticals Inc. (NASDAQ:CNAT) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - July 11 at 8:28 PM
nasdaq.com logoHealth Care Sector Update for 07/07/2017: CNAT,NVO,ARNA,DXTR ... - Nasdaq
www.nasdaq.com - July 8 at 5:02 PM
247wallst.com logoWhy Conatus Pharma Wins With Newest Licensing Agreement - 24/7 Wall St.
247wallst.com - July 8 at 5:02 PM
finance.yahoo.com logoWhy Conatus Pharma Wins With Newest Licensing Agreement
finance.yahoo.com - July 8 at 9:54 AM
globenewswire.com logoConatus Announces Effectiveness of Exclusive License for Global ... - GlobeNewswire (press release)
globenewswire.com - July 6 at 11:37 PM
seekingalpha.com logoConatus Pharmaceuticals announces effectiveness of Novartis license - Seeking Alpha
seekingalpha.com - July 6 at 11:37 PM
finance.yahoo.com logoConatus Announces Effectiveness of Exclusive License for Global Development and Commercialization of Emricasan with Receipt of $7 Million Payment
finance.yahoo.com - July 6 at 6:36 PM
americanbankingnews.com logo Analysts Anticipate Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Will Post Quarterly Sales of $7.93 Million
www.americanbankingnews.com - July 5 at 10:46 AM
americanbankingnews.com logoConatus Pharmaceuticals Inc. (CNAT) Expected to Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - July 3 at 6:30 PM
finance.yahoo.com logoH.C. Wainwright Bullish on Conatus Pharmaceuticals Inc (CNAT) on Back of Orphan Drug Designation for IDN-7314
finance.yahoo.com - June 29 at 6:35 PM
americanbankingnews.com logoConatus Pharmaceuticals Inc. (CNAT) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - June 29 at 7:34 AM
zacks.com logoConatus's PSC Candidate Gets Orphan Designation in the U.S.
www.zacks.com - June 27 at 4:37 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Moleculin Biotech and Conatus Pharmaceuticals
finance.yahoo.com - June 27 at 4:37 PM

Social

Chart

Conatus Pharmaceuticals (CNAT) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff